Chaoyang Fuxiang Pharmaceutical

Chaoyang Fuxiang Pharmaceutical is a specialized manufacturer of high-end pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), primarily serving the global anti-infective market. As a key subsidiary of Jiangxi Fuxiang Pharmaceutical, the company is one of the world's largest producers of beta-lactamase inhibitors such as Tazobactam and Sulbactam. Their product portfolio also includes critical carbapenem intermediates like 4-AA and antiviral components used in the production of COVID-19 treatments. The company's manufacturing facilities in Chaoyang, China, are designed to meet international GMP standards, ensuring high-quality supply for major pharmaceutical partners worldwide. By focusing on complex chemical synthesis and large-scale production, Chaoyang Fuxiang Pharmaceutical maintains a significant position in the supply chain for essential antibiotics and antiviral medications.